The Cardio-Renal Connection
This article was originally published in Start Up
Executive Summary
Clinicians are increasingly recognizing that the combination of renal dysfunction and heart failure appears to hasten the decline of patients with chronic heart failure (CHF), and even to increase their death rates. This is a significant observation because in one million annual hospital admissions for acute decompensated heart failure each year, 80% of patients have some degree of renal insufficiency. Now, several new device companies targeting cardio-renal syndrome hope to attack heart failure from a new vantage point: the kidney.
You may also be interested in...
Baxter Acquires Gambro, Becomes Integrated Renal Therapy Leader
Baxter’s offer of $4 billion for Swedish hemodialysis manufacturer Gambro may be one of the largest medtech acquisitions of the year, but Baxter CEO Bob Parkinson describes the deal as a bolt-on for Baxter’s existing market in renal therapy. Of course the magnitude of the deal makes it “an adjacency with a capital A”, Parkinson quipped.
Masterminds of Ardian: An Interview With Inventors Mark Gelfand and Howard Levin
Start-Up interviews the inventors behind Ardian, the object of one of the highest priced venture capital-backed medical device acquisitions, and between them, five other medical device companies. The team uniquely brings a perspective of applied physiology, and the integration of systems, to the goal of device innovation. In CHF Solutions, they've addressed heart failure with a device from nephrology, in Cardiac Conetps, heart failure by way of a neurological approach to sleep apnea, and in Ardian, hypertension, by studying the functioning of the kidney.
Ardian: Succeeding Where Drugs Fail--Treating Hypertension in the Cath Lab
Using the first catheter therapy for the interventional treatment of hypertension, this start-up's technology may be able to reduce blood pressure where drugs have not worked, and holds future promise for heart failure and kidney disease.